Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination.

Published in:

Virology Journal, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12985-024-02335-9

By:

• Cheng, Samuel M.S.;
• Mok, Chris K.P.;
• Li, John K.C.;
• Chan, Ken K.P.;
• Luk, Kristine S.;
• Lee, Ben H.W.;
• Gu, Haogao;
• Chan, Karl C.K.;
• Tsang, Leo C.H.;
• Yiu, Karen Y.S.;
• Ling, Ken K.C.;
• Tang, Yun Sang;
• Luk, Leo L.H.;
• Yu, Jennifer K.M.;
• Pekosz, Andrew;
• Webby, Richard J.;
• Cowling, Benjamin J.;
• Hui, David S.C.;
• Peiris, Malik

Publication type:

Article